-
Medieval tower collapse adds to Italy's workplace toll
-
BMW boosts profitability despite China, tariff woes
-
South Africa's Wiese wary of 'hurt' France before re-match
-
Asian markets sink as tech bubble fears grow
-
Beyond limits: Croatian freediver's breathtaking record
-
Tottenham supporting Udogie after alleged gun threat in London
-
Thunder roll Clippers to stay unbeaten as SGA keeps streak alive
-
In appeal, Australian mushroom murderer alleges 'miscarriage of justice'
-
Toyota hikes profit forecasts 'despite US tariffs'
-
Typhoon death toll soars past 90 in the Philippines
-
Ex-France lock Willemse challenges Meafou to become 'the bully'
-
Ukrainians to honour sporting dead by building country they 'died for': minister
-
At least 7 dead after UPS cargo plane crashes near Louisville airport
-
US Supreme Court hears challenge to Trump tariff powers
-
US government shutdown becomes longest in history
-
India's Modi readies bellwether poll in poorest state
-
Green goals versus growth needs: India's climate scorecard
-
Where things stand on China-US trade after Trump and Xi talk
-
Sri Lanka targets big fish in anti-corruption push
-
NY elects leftist mayor on big election night for Democrats
-
Injured Jordie Barrett to miss rest of All Blacks tour
-
Asian markets tumble as tech bubble fears grow
-
Pay to protect: Brazil pitches new forest fund at COP30
-
Australia pick 'impressive' Weatherald in first Ashes Test squad
-
Iraq's social media mercenaries dying for Russia
-
Young leftist Trump foe elected New York mayor
-
Concerns at ILO over expected appointment of close Trump advisor
-
Venus Williams to return to Auckland Classic at the age of 45
-
No deal yet on EU climate targets as COP30 looms
-
Typhoon death toll climbs to 66 in the Philippines
-
NATO tests war preparedness on eastern flank facing Russia
-
Uncapped opener Weatherald in Australia squad for first Ashes Test
-
Liverpool down Real Madrid in Champions League, Bayern edge PSG
-
Van Dijk tells Liverpool to keep calm and follow Arsenal's lead
-
PSG left to sweat on injuries to Dembele and Hakimi
-
Reddit, Kick to be included in Australia's social media ban
-
Ex-Zimbabwe cricket captain Williams treated for 'drug addiction'
-
Padres ace Darvish to miss 2026 MLB season after surgery
-
Diaz hero and villain as Bayern beat PSG in Champions League showdown
-
Liverpool master Real Madrid on Alexander-Arnold's return
-
Van de Ven back in favour as stunning strike fuels Spurs rout
-
Juve held by Sporting Lisbon in stalling Champions League campaign
-
New lawsuit alleges Spotify allows streaming fraud
-
Stocks mostly drop as tech rally fades
-
LIV Golf switching to 72-hole format in 2026: official
-
'At home' Djokovic makes winning return in Athens
-
Manchester City have become 'more beatable', says Dortmund's Gross
-
Merino brace sends Arsenal past Slavia in Champions League
-
Djokovic makes winning return in Athens
-
Napoli and Eintracht Frankfurt in Champions League stalemate
US tells pharmas to make Covid boosters targeting BA.4 and BA.5
The US Food and Drug Administration on Thursday told vaccine makers that Covid boosters for this fall and winter should include components targeting the BA.4 and BA.5 sublineages of Omicron.
Earlier this week, a panel of medical experts convened by the agency voted in favor of updating Covid vaccines against Omicron, with most indicating they would favor shots that target the latest iterations rather than its original form, BA.1, fearing the latter would be too out-of-date.
BA.4 and BA.5, which are more transmissible and immune evasive, now comprise more than 52 percent of US Covid cases, according to an official tracker.
"We have advised manufacturers seeking to update their Covid-19 vaccines that they should develop modified vaccines that add an omicron BA.4/5 spike protein component to the current vaccine composition to create a two component (bivalent) booster vaccine," the FDA said in a statement.
These vaccines would also need to target the original Wuhan strain, in order to increase the breadth of immune response.
Pfizer and Moderna, which produce messenger RNA Covid vaccines, have developed and tested vaccines against BA.1, and representatives of both companies indicated during the experts' meeting they would need around three months to produce BA.4 and BA.5 vaccines at scale.
Pfizer shared early results showing its BA.4/5 vaccine produced a strong antibody response in mice, but it hasn't yet been trialed in humans.
Novavax, which makes a protein subunit vaccine, said it could offer BA.4/5 vaccines by the end of the year.
The FDA said in its new statement that the companies would need to submit human data prior to authorization.
The "primary series" or first shots a person receives would remain against the original strain, the FDA added.
While previous "variants of concern" like Alpha and Delta eventually petered out, Omicron and its sublineages have dominated throughout 2022, to the point it comprises the vast majority of all Covid in the world, FDA official Jerry Weir told the expert meeting this week.
This makes it more likely that the virus's future evolution will also occur along the Omicron branch of the Covid family tree, he added.
Earlier this month, the World Health Organization also recommended the use of Omicron boosters after a primary series against the original strain.
K.AbuTaha--SF-PST